Long-time Zomedica holder argues the stock is severely undervalued given 20 consecutive quarters of revenue growth, new patented products, and international distribution deals, and says he is buying.
ZOM — LONG The author, holding 320,000 shares, argues Zomedica is severely undervalued because of revenue growth in 20 consecutive quarters, multiple new products approved with patents, and international distribution agreements. He cites a long coiling bull flag as shorts have been driven out, a CEO public commitment to no more reverse splits, and strong holder resistance to selling. He states he is a buyer.
The market is not yet convinced, despite revenue growth in 20 consecutive quarters, multiple new products approved with patents, and international distribution agreements. All that said, this stock is severely undervalued.
This Reddit post, published January 24, 2026, features u/BigDaddyJohnJohn discussing ZOM. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/BigDaddyJohnJohn · Tickers: ZOM